Compare SLDP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | ARVN |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.5M | 516.2M |
| IPO Year | 2021 | 2018 |
| Metric | SLDP | ARVN |
|---|---|---|
| Price | $2.43 | $8.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $7.00 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 3.9M | 835.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.56 | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | $21,747,000.00 | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | N/A |
| P/E Ratio | ★ N/A | $5.28 |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $1.98 | $6.74 |
| 52 Week High | $8.86 | $14.22 |
| Indicator | SLDP | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 61.46 |
| Support Level | $2.21 | $7.90 |
| Resistance Level | $2.51 | $9.65 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 93.00 | 62.11 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.